In July, the editors from AACR's 10 peer-reviewed journals highlighted research on AI-driven molecular mapping of pancreatic cancer evolution, sex differences in immune responses, the discovery of a new subset of cells that promote...
The summer issue of Cancer Today includes articles about integrating patient-reported outcomes into clinical research and care, advances in preventing and treating graft-versus-host disease, researchers’ efforts to better understand the mechanisms of treatment resistance,...
During the opening session of the AACR Conference on Drug Discovery and Development, the conference cochairs—Patricia M. LoRusso, DO, PhD (hc), FAACR; Keith T. Flaherty MD, FAACR; Lillian L. Siu, MD, FAACR; and Timothy...
Zidesamtinib, a next-generation ROS1 inhibitor, was approved for ROS1-positive NSCLC previously treated with ROS1 inhibition. The U.S. Food and Drug Administration (FDA) has approved zidesamtinib (Jideytro), a next-generation ROS1 inhibitor, for adults with locally...
At the recent AACR Special Conference on Breaking Barriers in the Fight Against Rare Cancers, AACR Immediate Past President Lillian L. Siu, MD, FAACR, announced the AACR Rare Cancers Initiative. Learn more about how...
A targeted therapy inhibits multiple proteins in a common signaling pathway for breast cancer, and disparities researchers feel the impact of shifting federal priorities.
Cancer immunology expert and former AACR president Elizabeth Jaffee, MD, FAACR, discusses the latest progress in the research on pancreatic cancer vaccines and explains why cancer interception in individuals at high risk is the...
Gedatolisib received its first FDA approval for advanced HR-positive, HER2-negative breast cancer without mutations in PIK3CA. The U.S. Food and Drug Administration (FDA) has approved gedatolisib (Revtorpyk) in combination with fulvestrant (Faslodex), with or...
The RET inhibitor received traditional approval to treat RET-fusion-positive solid tumors. The U.S. Food and Drug Administration (FDA) has granted full approval to selpercatinib (Retevmo) to treat RET-fusion-positive solid tumors in adult and pediatric...
Exposure to wildfire smoke may increase the risk of developing several cancers, according to research presented at the AACR Annual Meeting 2026 by Shuguang Leng, MBBS, PhD, and Qizhen Wu, PhD, both of the...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More